CNM-Au8 is an oral suspension with demonstrated activity in restoring neuronal health and function by increasing energy production and utilization Treatment with CNM-Au8 investigated in clinical ...
Clene (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as MS Treatment Presented at AAN Conference
The data, which demonstrates improved clinical, functional and structural outcomes associated with daily oral dosing of CNM-Au8 30 mg. for up to three years of treatment, was presented by Dr ...
Long-term treatment with Clene Nanomedicine‘s experimental oral therapy CNM-Au8 led to signs of sustained improvements in nerve and myelin health for people with relapsing-remitting multiple ...
The data, which demonstrates improved clinical, functional and structural outcomes associated with daily oral dosing of CNM-Au8 30 mg. for up to three years of treatment, was presented by Dr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback